Variable | Number of patients (N) | DTC+ at BM1 n/number assessedd (%) | P-value | DTC+ at BM3 n/number assessedd (%) | P-value |
---|---|---|---|---|---|
Total number | 236 | 49/231 (21.2) | 43/162 (26.5) | ||
Median age, years (range) | 51 (25-70) | ||||
cT status: | 0.471b | 0.659b | |||
cT0-cT3 | 187 | 37/183 (20.2) | 36/132 (27.3) | ||
cT4 | 49 | 12/48 (25.0) | 7/30 (23.3) | ||
cN status | 0.654b | 0.203b | |||
cN0 | 98 | 19/95 (20.0) | 15/69 (21.7) | ||
cN1 | 104 | 21/103 (20.4) | 20/74 (27.0) | ||
cN2-4 | 34 | 9/33 (27.3) | 8/19 (42.1) | ||
M status | 0.162b | 0.109ª | |||
M1 | 25 | 8/25 (32.0) | 6/13 (46.2) | ||
M0 | 211 | 41/206 (19.9) | 37/149 (24.8) | ||
Hormone receptor status | |||||
Estrogen receptor | 0.332ª | 0.816ª | |||
ER-pos | 133 | 32/131 (24.4) | 27/101 (26.7) | ||
ER-neg | 98 | 16/95 (16.8) | 16/58 (27.6) | ||
Unknown | 5 | ||||
Progesterone receptor | 0.072ª | 0.478ª | |||
PgR-pos | 113 | 30/110 (27.3) | 26/88 (29.5) | ||
PgR-neg | 118 | 18/116 (15.5) | 16/71 (22.5) | ||
Unknown | 5 | ||||
Histological grade | 0.666b | 0.960ª | |||
Grade 1 | 14 | 4/13 (30.8) | 3/12 (25.0) | ||
Grade 2 | 98 | 21/96 (21.9) | 20/72 (27.8) | ||
Grade 3 | 110 | 22/108 (20.4) | 18/72 (25.0) | ||
Unknown | 14 | ||||
Response | 1.000ª | 0.784ª | |||
Complete response | 10 | 2/10 (20.0) | 1/6 (16.7) | ||
Partial response | 108 | 22/104 (21.2) | 19/79 (24.1) | ||
Stable disease | 88 | 18/87 (20.7) | 15/61 (24.6) | ||
Progression | 6 | 1/6 (16.7) | 1/2 (50.0) | ||
Unknown | 24 | ||||
BM1 status (pretreatment) | 0.077b | ||||
Positive | 49 | 14/37 (37.8) | |||
Negative | 182 | 28/121 (23.1) | |||
Unknown | 5 | ||||
BM2 status (at surgery) | 1.000ª | 0.654ª | |||
Positive | 11 | 2/11 (18.2) | 1/7 (14.3) | ||
Negative | 58 | 9/55 (16.4) | 12/38 (31.6) | ||
Unknown | 167 | ||||
BM3 status (at 1 year follow-up) | 0.077b | ||||
Positive | 43 | 14/42 (33.3) | |||
Negative | 119 | 23/116(19.8) | |||
Unknown | 74 | ||||
PB1 status (pretreatment) | 0.033ª | 0.464ª | |||
Positive | 10 | 5/10 (50.0) | 1//2 (50.0) | ||
Negative | 209 | 39/204 (19.1) | 39/148 (26.4) | ||
Unknown | 17 | ||||
PB2 status (at surgery) | 1.000ª | 0.298ª | |||
Positive | 1 | 0/1 (0) | 1/1 (100.0) | ||
Negative | 70 | 12/67 (17.9) | 13/46 (28.2) | ||
Unknown | 165 | ||||
PB3 status (at 1 year follow-up) | 0.618ª | 0.004ª | |||
Positive | 6 | 2/6 (33.3) | 5/6 (83.3) | ||
Negative | 135 | 29/131 (22.1) | 30/133 (22.6) | ||
Unknown | 95 | ||||
Relapse c | 0.642b | 0.005b | |||
Yes | 98 | 22/98 (22.4) | 22/55 (40.0) | ||
No | 112 | 21/107 (19.6) | |||
Relapse type | |||||
Locoregional only | 4 | 0/4 (0) | 0/2 (0) | ||
Distant metastases (skeletal and/or visceral) | 76 | 18/74 (24.3) | 15/42 (35.7) | ||
Distant metastases and locoregional | 18 | 4/18 (22.2) | 7/11 (63.6) | ||
Death and cause e | |||||
Breast cancer death | 106 | 23/105 (21.9) | 26/53 (49.1) | ||
Any death | 111 | 25/110 (22.7) | 27/57 (47.4) | ||
Alive | 124 | 24/120 (20.0) | 16/105 (15.2) |